Murine Cyp3a knockout chimeric mice with humanized liver: Prediction of the metabolic profile of nefazodone in humans

Biopharmaceutics and Drug Disposition

Volumn 37, Issue 1, 2016, Pages 3-14

  Nakada, Naoyuki ^a   Kawamura, Akio ^a   Kamimura, Hidetaka ^b   Sato, Koya ^a   Kazuki, Yasuhiro ^c   Kakuni, Masakazu ^d   Ohbuchi, Masato ^a   Kato, Kota ^a   Tateno, Chise ^d,e   Oshimura, Mitsuo ^c   Usui, Takashi ^a  

^a ASTELLAS PHARMA INC   (Japan)

^b SEKISUI CHEMICAL CO LTD   (Japan)

^c TOTTORI UNIVERSITY   (Japan)

^d PhoenixBio USA Corporation   (Japan)

^e HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Cyp3a knockout; nefazodone; predicting the metabolic profiles of drug candidates in humans

Indexed keywords

CYTOCHROME P450 3A; NEFAZODONE; ANTIDEPRESSANT AGENT; TRIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CHIMERA; CONTROLLED STUDY; DRUG METABOLISM; GENE INACTIVATION; HUMAN; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; LIVER; LIVER METABOLISM; LIVER MICROSOME; MALE; METABOLIC RATE; MOUSE; MOUSE STRAIN; NONHUMAN; ORAL CLEARANCE; PHARMACOKINETIC PARAMETERS; SCID MOUSE; SEVERE COMBINED IMMUNODEFICIENCY; SINGLE DRUG DOSE; ANIMAL; BILE; BLOOD; CHEMISTRY; GENETICS; INSTITUTE FOR CANCER RESEARCH MOUSE; KNOCKOUT MOUSE; LIVER CELL; METABOLISM; PRESCHOOL CHILD; URINE;

ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BILE; CHILD, PRESCHOOL; CYTOCHROME P-450 CYP3A; HEPATOCYTES; HUMANS; LIVER; MALE; MICE, INBRED ICR; MICE, KNOCKOUT; MICE, SCID; MICROSOMES, LIVER; TRIAZOLES;

EID: 84957309060     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.1990     Document Type: Article

References (37)

1. Smith DA, Dalvie D,. Why do metabolites circulate? Xenobiotica 2012; 42: 107-126. doi: 10.3109/00498254.2011.630110.
2. Testa B, Pedretti A, Vistoli G,. Reactions and enzymes in the metabolism of drugs and other xenobiotics. Drug Discov Today 2012; 17: 549-560. doi: 10.1016/j.drudis.2012.01.017.S1359-6446(12)00035-9[pii].
3. FDA. Guidance for Industry: Safety Testing of Drug Metabolites. Food and Drug Administration: Rockville, MD, USA, 2008.
4. ICH. ICH Guideline M3 (R2): Guidance on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals. International Conference on Harmonisation: Geneva, Switzerland, 2009.
5. Dalvie D, Obach RS, Kang P, et al., Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites. Chem Res Toxicol 2009; 22: 357-368. doi: 10.1021/tx8004357.10.1021/tx8004357[pii].
6. Wang Q, Jia R, Ye C, Garcia M, Li J, Hidalgo IJ,. Glucuronidation and sulfation of 7-hydroxycoumarin in liver matrices from human, dog, monkey, rat, and mouse. In Vitro Cell Dev Biol Anim 2005; 41: 97-103. doi:0501005[pii].10.1290/0501005.1.
7. Tateno C, Yoshizane Y, Saito N, et al., Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am J Pathol 2004; 165: 901-912. doi:S0002-9440(10)63352-4[pii].10.1016/S0002-9440(10)63352-4.
8. Katoh M, Matsui T, Nakajima M, et al., Expression of human cytochromes P450 in chimeric mice with humanized liver. Drug Metab Dispos 2004; 32: 1402-1410. doi: 10.1124/dmd.104.001347.dmd.104.001347[pii].
9. Katoh M, Matsui T, Okumura H, et al., Expression of human phase II enzymes in chimeric mice with humanized liver. Drug Metab Dispos 2005; 33: 1333-1340. doi:dmd.105.005157[pii].10.1124/dmd.105.005157.
10. Inoue T, Sugihara K, Ohshita H, Horie T, Kitamura S, Ohta S,. Prediction of human disposition toward S-3H-warfarin using chimeric mice with humanized liver. Drug Metab Pharmacokinet 2009; 24: 153-160. doi:JST.JSTAGE/dmpk/24.153[pii].
11. Kamimura H, Nakada N, Suzuki K, et al., Assessment of chimeric mice with humanized liver as a tool for predicting circulating human metabolites. Drug Metab Pharmacokinet 2010; 25: 223-235. doi:JST.JSTAGE/dmpk/25.223[pii].
12. Yamazaki H, Kuribayashi S, Inoue T, et al., Approach for in vivo protein binding of 5-n-butyl-pyrazolo[1,5-a]pyrimidine bioactivated in chimeric mice with humanized liver by two-dimensional electrophoresis with accelerator mass spectrometry. Chem Res Toxicol 2010; 23: 152-158. doi: 10.1021/tx900323a.
13. De Serres M, Bowers G, Boyle G, et al., Evaluation of a chimeric (uPA+/+)/SCID mouse model with a humanized liver for prediction of human metabolism. Xenobiotica 2011; 41: 464-475. doi: 10.3109/00498254.2011.560295.
14. Nakada N, Oda K,. Identification and characterization of metabolites of ASP015K, a novel oral Janus kinase inhibitor, in rats, chimeric mice with humanized liver, and humans. Xenobiotica 2015; 45: 757-765. doi: 10.3109/00498254.2015.1019594.
15. Sanoh S, Horiguchi A, Sugihara K, et al., Prediction of in vivo hepatic clearance and half-life of drug candidates in human using chimeric mice with humanized liver. Drug Metab Dispos 2012; 40: 322-328. doi: 10.1124/dmd.111.040923.dmd.111.040923[pii].
16. Sanoh S, Naritomi Y, Fujimoto M, et al., Predictability of plasma concentration-time curves in humans using single-species allometric scaling of chimeric mice with humanized liver. Xenobiotica 2015; 45: 605-614.
17. Hall SD, Thummel KE, Watkins PB, et al., Molecular and physical mechanisms of first-pass extraction. Drug Metab Dispos 1999; 27: 161-166.
18. Dresser GK, Spence JD, Bailey DG,. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000; 38: 41-57.
19. Guengerich FP,. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 1999; 39: 1-17. doi: 10.1146/annurev.pharmtox.39.1.1.
20. van Herwaarden AE, Wagenaar E, van der Kruijssen CM, et al., Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism. J Clin Invest 2007; 117: 3583-3592. doi: 10.1172/JCI33435.
21. van Waterschoot RA, Lagas JS, Wagenaar E, et al., Absence of both cytochrome P450 3A and P-glycoprotein dramatically increases docetaxel oral bioavailability and risk of intestinal toxicity. Cancer Res 2009; 69: 8996-9002. doi:10.1158/0008-5472.CAN-09-2915.0008-5472.CAN-09-2915[pii].
22. van Waterschoot RA, Schinkel AH,. A critical analysis of the interplay between cytochrome P450 3A and P-glycoprotein: recent insights from knockout and transgenic mice. Pharmacol Rev 2011; 63: 390-410. doi: 10.1124/pr.110.002584.pr.110.002584[pii].
23. Hashimoto M, Kobayashi K, Watanabe M, et al., Knockout of mouse Cyp3a gene enhances synthesis of cholesterol and bile acid in the liver. J Lipid Res 2013; 54: 2060-2068. doi:jlr.M033464[pii].10.1194/jlr.M033464.
24. Kazuki Y, Kobayashi K, Aueviriyavit S, et al., Trans-chromosomic mice containing a human CYP3A cluster for prediction of xenobiotic metabolism in humans. Hum Mol Genet 2013; 22: 578-592. doi: 10.1093/hmg/dds468.dds468[pii].
25. Kato K, Ohbuchi M, Hamamura S, et al., Development of murine Cyp3a knockout chimeric mice with humanized liver. Drug Metab Dispos 2015; 43: 1208-1217. doi:dmd.115.063479[pii].10.1124/dmd.115.063479.
26. Barbhaiya RH, Buch AB, Greene DS,. A study of the effect of age and gender on the pharmacokinetics of nefazodone after single and multiple doses. J Clin Psychopharmacol 1996; 16: 19-25.
27. Barbhaiya RH, Dandekar KA, Greene DS,. Pharmacokinetics, absolute bioavailability, and disposition of [14C]nefazodone in humans. Drug Metab Dispos 1996; 24: 91-95.
28. Barbhaiya RH, Shukla UA, Natarajan CS, Behr DA, Greene DS, Sainati SM,. Single- and multiple-dose pharmacokinetics of nefazodone in patients with hepatic cirrhosis. Clin Pharmacol Ther 1995; 58: 390-398. doi:0009-9236(95)90051-9[pii].10.1016/0009-9236(95)90051-9.
29. Greene DS, Barbhaiya RH,. Clinical pharmacokinetics of nefazodone. Clin Pharmacokinet 1997; 33: 260-275. doi: 10.2165/00003088-199733040-00002.
30. Kalgutkar AS, Vaz AD, Lame ME, et al., Bioactivation of the nontricyclic antidepressant nefazodone to a reactive quinone-imine species in human liver microsomes and recombinant cytochrome P450 3A4. Drug Metab Dispos 2005; 33: 243-253. doi:dmd.104.001735[pii].10.1124/dmd.104.001735.
31. Kennett GA, Whitton P, Shah K, Curzon G,. Anxiogenic-like effects of mCPP and TFMPP in animal models are opposed by 5-HT1C receptor antagonists. Eur J Pharmacol 1989; 164: 445-454.
32. Rajkumar R, Pandey DK, Mahesh R, Radha R,. 1-(m-Chlorophenyl)piperazine induces depressogenic-like behaviour in rodents by stimulating the neuronal 5-HT(2A) receptors: proposal of a modified rodent antidepressant assay. Eur J Pharmacol 2009; 608: 32-41. doi: 10.1016/j.ejphar.2009.02.041.S0014-2999(09)00198-8[pii].
33. von Moltke LL, Greenblatt DJ, Granda BW, et al., Nefazodone, meta-chlorophenylpiperazine, and their metabolites in vitro: cytochromes mediating transformation, and P450-3A4 inhibitory actions. Psychopharmacology (Berl) 1999; 145: 113-122.
34. Rotzinger S, Baker GB,. Human CYP3A4 and the metabolism of nefazodone and hydroxynefazodone by human liver microsomes and heterologously expressed enzymes. Eur Neuropsychopharmacol 2002; 12: 91-100. doi:S0924977X02000056[pii].
35. Mayol RF, Cole CA, Luke GM, Colson KL, Kerns EH,. Characterization of the metabolites of the antidepressant drug nefazodone in human urine and plasma. Drug Metab Dispos 1994; 22: 304-311.
36. Peterman SM, Duczak N Jr, Kalgutkar AS, Lame ME, Soglia JR,. Application of a linear ion trap/orbitrap mass spectrometer in metabolite characterization studies: examination of the human liver microsomal metabolism of the non-tricyclic anti-depressant nefazodone using data-dependent accurate mass measurements. J Am Soc Mass Spectrom 2006; 17: 363-375. doi:S1044-0305(05)00988-8[pii].10.1016/j.jasms.2005.11.014.
37. Li AC, Shou WZ, Mai TT, Jiang XY,. Complete profiling and characterization of in vitro nefazodone metabolites using two different tandem mass spectrometric platforms. Rapid Commun Mass Spectrom 2007; 21: 4001-4008. doi: 10.1002/rcm.3303.